kin-3248

·Code: KIN-3248

kin-3248: developed by 1 company · 1 clinical trial tracked. Updated within the last hour.

Development Pipeline (1)

Clinical Trials (1)

A Phase 1/1b, Open-label, Multicenter Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Anti-tumor Activity of KIN-3248 in Participants With Advanced Tumors Harboring FGFR2 and/or FGFR3 Gene Alterations

NCT05242822·Phase 1·KNTE
Terminated

Frequently asked questions

Who is developing kin-3248?

kin-3248 is being developed by KINNATE BIOPHARMA INC..

How many clinical trials involve kin-3248?

BioSniper tracks 1 clinical trial involving kin-3248.

Get deeper analysis on kin-3248

Full trial data, mechanism of action, competitive landscape, and AI-powered insights.

Start Free Analysis
    kin-3248 — Drug Pipeline, Trials & FDA Status | BioSniper